Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-02-16
2004-12-28
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S300000, C530S333000, C530S402000, C435S032000, C424S009100, C424S439000, C604S019000
Reexamination Certificate
active
06835713
ABSTRACT:
BACKGROUND OF THE INVENTION
The development of antimicrobial agents has led to a significant decrease in morbidity and mortality from infectious diseases in this century. This important public health contribution has been largely due to the widespread use of antibiotics that target specific nutrient, cell wall, DNA, RNA and protein biosynthetic pathways that are peculiar to pathogenic bacteria. However, in recent years the capacity to manage infectious diseases has been threatened by the emergence of bacterial strains that are no longer susceptible to currently available antimicrobial agents (see Files, 1999,
Chest.
115:3S-8S). Maintenance of the public heath mandates that new antimicrobial agents need to be developed to counter these emerging resistant bacteria in order for effective infectious disease management procedures to remain in place.
A heterogeneous group of host-derived antimicrobial peptides have drawn attention as possible new therapeutic agents (see Hancock, R. E., 1999,
Drugs
57:469-473). These peptides play an important role in innate vertebrate immunity against infection. For example, cationic antimicrobial peptides constitute as much as 18% by weight of total neutrophil protein. They are also found in high concentrations on damaged mucosal surfaces. In general these host-derived cationic peptides fit into one of four structural categories: (i) &bgr;-sheet structures that are stabilized by multiple disulfide bonds (e.g., human defensin-1), (ii) covalently stabilized loop structures (e.g., bactenecin), (iii) tryptophan (Trp)-rich, extended helical peptides (e.g., indolicidin), and (iv) amphipathic &agr;-helices (e.g., the magainins and cecropins) (see Hwang and Vogel, 1998,
Biochemistry
&
Cell Biology
76:235-246). Recently a new class of antimicrobial peptides, the cathelicidins, that utilize all of these structural motifs and are clearly important in host defense against infection has been described (Ganz and Lehrer, 1997,
Current Opinion in Hematology
4:53-58).
The cathelicidins are a remarkably diverse collection of molecules that derive from prepropeptides sharing a highly conserved N-terminal propeptide segment that have been described in humans, cattle, sheep, rabbits, mice, and pigs (see Hwang and Vogel, 1998,
Biochemistry
&
Cell Biology
76:235-246). The conserved propeptide segment of approximately 100 amino acids shares sequence similarity with the porcine protein cathelin, a putative cysteine protease inhibitor, hence the family name. The C-terminal domain encodes an antimicrobial peptide motif similar to one of those described above, depending upon the host and tissue that it is associated with. Cathelicidins are stored in neutrophil granules as propeptides (lacking antimicrobial activity in this form), with neutrophil activation leading to elastase-mediated endoproteolytic cleavage and generation of the C-terminal antimicrobial peptide. The human cathelicidin, referred to alternatively as FALL-39, hCAP18, LL-37, or CAMP, in its processed (active) form is a 37-amino acid amphiphilic &agr;-helical cationic peptide (see Zanetti, Gennaro and Romeo, 1995,
FEBS Letters
374:1-5). Expression of LL-37 has been detected in human neutrophils, testicular cells, respiratory epithelia, and in keratinocytes at sites of inflammation.
The amphipathic cationic peptides of the &agr;-helical class demonstrate minimal bactericidal concentrations (MBCs) in the &mgr;g/mL range (levels equivalent to other antimicrobial agents) and are able to kill a broad range of gram-negative and gram-positive bacterial pathogens, including those that are highly resistant to multiple antibiotics (see Hancock, R. E., 1999,
Drugs
57:469-473). The mechanism by which these peptides kill bacteria proceeds in a two step process by first binding to the negatively charged bacterial surface and driving these bound peptides into the bacterial membrane, thereby disrupting its structural integrity. For gram-negative organisms, cationic antimicrobial peptides have the added advantage of binding lipopolysaccharide (LPS), thereby detoxifying its endotoxic activity (see Scott, Yan, and Hancock, 1999,
Infection
&
Immunity
67:2005-2009). The hallmark of amphipathic cationic &agr;-helical antimicrobial peptides is their capacity to fold into an amphipathic secondary structure that presents a hydrophilic face with a net positive charge of at least +2. A number of different amino acid sequence combinations allow a peptide to achieve this characteristic structure. Consequently, hundreds of host-derived amphipathic cationic &agr;-helical peptides have been described to date all showing limited sequence homology at the level of primary sequence comparison (see Hwang and Vogel, 1998,
Biochemistry
&
Cell Biology
76:235-246).
In contrast to host derived antimicrobial peptides, which have evolved with the express purpose of killing bacteria, a novel class of antimicrobial peptides derived from discrete segments of the lentiviral transmembrane (TM) protein cytoplasmic tail has been described that have not evolved for the same purpose as host-derived peptides (see Beary et al., 1998,
Journal of Peptide Research
51:75-79; Comardelle et al., 1997,
AIDS Research
&
Human Retroviruses
13:1525-1532; Miller et al., 1993,
AIDS Research
&
Human Retroviruses
9:1057-1066; Miller et al., 1993,
Virology
196:89-1000; Tencza et al., 1995,
Virology
69:5199-5202; Tencza et al., 1997,
Antimicrobial Agents
&
Chemotherapy
41:2394-2398; Tencza et al., 1997,
AIDS Research
&
Human Retroviruses
13:263-269; Yuan et al., 1995,
Biochemistry
34:10690-10696). These peptides are referred to as lentiviral lytic peptides (LLPs) with the prototypical LLP being LLP1 (amino acids 828-856 of the HIV-1 viral isolate HXB2R Env). LLP1 is derived from the 28-residues encoded by the C-terminal portion of the HIV-1 TM protein that, when modeled as an &agr;-helix, demonstrates amphipathic character with clearly delineated cationic and hydrophobic faces. Among the many antimicrobial peptides currently described in the literature, LLP1 is most homologous chemically to the magainins and the human cathelicidin, LL37.
LLP1 has been studied for its calmodulin-binding and antibacterial properties. LLP1 binds to host cell Ca
2+
-saturated calmodulin with near nanomolar affinity and this property has been correlated with the inhibition of T-cell activation, suggesting that these peptides may dampen an inflammatory response (see Beary et al., 1998,
Journal of Peptide Research
51:75-79; Miller et al., 1993,
AIDS Research
&
Human Retroviruses
9:1057-1066; Tencza et al., 1995,
Virology
69:5199-5202; Tencza et al., 1997,
AIDS Research
&
Human Retroviruses
13:263-269; Yuan et al., 1995,
Biochemistry
34:10690-10696). LLP1 antibacterial activity has been investigated by surveying diverse gram-negative and -positive bacterial isolates. This analysis demonstrates that LLP1 has antibacterial activity which is equal to, or more potent than magainin-2. These isolates included methicillin and vancomycin resistant strains as well as other strains that were highly resistant to multiple antibiotics (see Tencza et al., 1997,
Antimicrobial Agents
&
Chemotherapy
41:2394-2398). The lysis of bacteria by LLP1 is rapid, nearly sterilizing a suspension of 1×10
5
colony-forming units of
Pseudomonas aeruginosa
or
Staphylococcus aureus
within 60 seconds of exposure (see Tencza et al., 1997,
Antimicrobial Agents
&
Chemotherapy
41:2394-2398). The mechanism of LLP1 action is thought to perturb negatively charged bacterial membranes, and to a lesser extent, neutral mammalian cell membranes. The predilection of the peptide for bacterial cells over mammalian cell membranes forms the basis for its selective toxicity.
Single amino acid changes in the LLP1 profoundly affect its calmodulin binding and antibacterial activity (see Tencza et al., 1995,
Virology
69:5199-5202; Tencza et al., 1999,
Journal of Antimicrobial Chemotherapy
44:33-41). In general, amino acid substitutions in the parent LLP1 sequence of
Mietzner Timothy A.
Montelaro Ronald C.
Baker & Botts L.L.P.
Carlson Karen Cochrane
Lin Samuel Wei
University of Pittsburgh
LandOfFree
Virus derived antimicrobial peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virus derived antimicrobial peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus derived antimicrobial peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3325333